NCT06690775 2025-12-23
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
TORL Biotherapeutics, LLC
Phase 2 Recruiting
Clinical Trials
51 trialsNCT05870748 2025-09-23
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Sutro Biopharma, Inc.
Phase 2/3 Terminated
NCT03646123 2025-08-28
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT03102606 2024-08-29
Protective-1
BeyondSpring Pharmaceuticals Inc.
Phase 3 Completed
NCT04345900 2024-05-16
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2
BeyondSpring Pharmaceuticals Inc.
Phase 2 Completed
NCT00837265 2024-04-03
NEUGR-002
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2/3 Completed
NCT03197935 2023-10-26
IMpassion031
Hoffmann-La Roche
Phase 3 Completed
NCT03252431 2023-07-03
Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 3 Completed
NCT01126190 2023-03-28
NEUGR-003
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3 Completed
NCT04584112 2023-03-15
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT01724866 2022-04-15
Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT02643420 2022-03-02
ADVANCE
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT02953340 2022-03-02
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide
Spectrum Pharmaceuticals, Inc
Phase 3 Completed
NCT02467868 2022-02-14
Efficacy and Safety Study With MYL-1401H and Neulasta
Viatris Inc.
Phase 3 Completed
NCT03511378 2021-06-15
Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer
Lupin Ltd.
Phase 4 Completed
NCT03294577 2021-01-15
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
BeyondSpring Pharmaceuticals Inc.
Phase 3 Unknown
NCT00211185 2020-03-18
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Eisai Inc.
Phase 2 Completed
NCT04227990 2020-01-18
Plinabulin iv Solution in Prevention of TAC Induced Neutropenia
BeyondSpring Pharmaceuticals Inc.
Phase 2 Completed
NCT00394251 2019-11-25
Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Celgene
Phase 2 Completed
NCT01059643 2019-09-18
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Eli Lilly and Company
Phase 2 Completed
NCT01416389 2019-09-18
A Study of LY2523355 in Participants With Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT03559387 2019-02-12
Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia
Prolong Pharmaceuticals
Phase 2 Terminated
NCT00094809 2018-10-17
Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer
Amgen
Phase 2 Completed
NCT01648322 2018-10-03
Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
EVIVE Biotechnology
Phase 2 Completed
NCT01214629 2018-08-06
A Study for Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01214642 2018-08-06
A Dose-Escalation Study for Patients With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01712009 2018-01-30
NOLAN
Amgen
Phase 2 Completed
NCT03404752 2018-01-19
Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.
Gema Biotech S.A.
Phase 3 Unknown
NCT03381417 2018-01-02
Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Phase 3 Completed
NCT00911170 2017-12-29
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Amgen
Phase 3 Completed
NCT03376503 2017-12-19
Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Phase 1 Completed
NCT01735175 2017-08-07
PROTECT-1
Sandoz
Phase 3 Completed
NCT00364468 2017-03-03
Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT02782845 2016-11-21
An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)
Hoffmann-La Roche
Phase 4 Completed
NCT02805153 2016-06-20
PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 4 Completed
NCT02805218 2016-06-20
PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 4 Completed
NCT02805166 2016-06-17
PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 4 Completed
NCT01585649 2016-05-18
PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Completed
NCT01519700 2015-05-06
PIONEER
Sandoz
Phase 3 Completed
NCT00115193 2013-08-29
Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma
Amgen
Phase 2 Completed
NCT00277160 2010-10-08
A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
Amgen
Phase 4 Completed
NCT00035620 2010-02-26
Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy
Amgen
Phase 2 Completed
NCT00124111 2010-02-26
A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer
Amgen
Phase 2 Completed
NCT00261313 2010-02-26
ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer
Amgen
Phase 2 Completed
NCT00117897 2009-07-20
Treatment for Subjects With Non-Hodgkin's Lymphoma
Amgen
Phase 2 Completed
NCT00115206 2009-04-06
Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy
Amgen
Phase 4 Completed
NCT00114764 2008-10-31
Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)
Amgen
Phase 2 Completed
NCT00115414 2008-08-01
Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)
Amgen
Phase 2 Completed
NCT00117455 2008-05-16
A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma
Amgen
Phase 2 Completed
NCT00117910 2008-05-16
Treatment for Elderly Patients With High Risk Breast Cancer
Amgen
Phase 3 Completed